Sign In
Buy AMPH
Amphastar Pharmaceuticals Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | $0.700 |
| EPS actual | $0.420 |
| EPS Surprise | -40.00% |
| Revenue estimate | 173.461M |
| Revenue actual | 171.171M |
| Revenue Surprise | -1.32% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.90 |
| EPS actual | $0.730 |
| EPS Surprise | -19.16% |
| Revenue estimate | 188.773M |
| Revenue actual | 183.105M |
| Revenue Surprise | -3.00% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.770 |
| EPS actual | $0.93 |
| EPS Surprise | 20.78% |
| Revenue estimate | 190.48M |
| Revenue actual | 191.84M |
| Revenue Surprise | 0.714% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.710 |
| EPS actual | $0.85 |
| EPS Surprise | 19.72% |
| Revenue estimate | 177.1M |
| Revenue actual | 174.414M |
| Revenue Surprise | -1.52% |
Last 4 Quarters for Amphastar Pharmaceuticals
Below you can see how AMPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $21.62 |
| EPS estimate | $0.710 |
| EPS actual | $0.85 |
| EPS surprise | 19.72% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $21.21 |
| Aug 04, 2025 | $21.40 |
| Aug 05, 2025 | $21.44 |
| Aug 06, 2025 | $20.82 |
| Aug 07, 2025 | $21.62 |
| Aug 08, 2025 | $23.81 |
| Aug 11, 2025 | $27.36 |
| Aug 12, 2025 | $30.35 |
| Aug 13, 2025 | $30.48 |
| 4 days before | 1.93% |
| 4 days after | 40.98% |
| On release day | 10.13% |
| Change in period | 43.71% |
| Release date | Nov 06, 2025 |
| Price on release | $24.23 |
| EPS estimate | $0.770 |
| EPS actual | $0.93 |
| EPS surprise | 20.78% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $25.50 |
| Nov 03, 2025 | $25.30 |
| Nov 04, 2025 | $25.26 |
| Nov 05, 2025 | $25.31 |
| Nov 06, 2025 | $24.23 |
| Nov 07, 2025 | $24.03 |
| Nov 10, 2025 | $26.12 |
| Nov 11, 2025 | $27.16 |
| Nov 12, 2025 | $27.83 |
| 4 days before | -4.98% |
| 4 days after | 14.86% |
| On release day | -0.83% |
| Change in period | 9.14% |
| Release date | Feb 26, 2026 |
| Price on release | $26.49 |
| EPS estimate | $0.90 |
| EPS actual | $0.730 |
| EPS surprise | -19.16% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $28.53 |
| Feb 23, 2026 | $27.55 |
| Feb 24, 2026 | $27.67 |
| Feb 25, 2026 | $27.97 |
| Feb 26, 2026 | $26.49 |
| Feb 27, 2026 | $20.23 |
| Mar 02, 2026 | $21.01 |
| Mar 03, 2026 | $19.83 |
| Mar 04, 2026 | $19.96 |
| 4 days before | -7.15% |
| 4 days after | -24.65% |
| On release day | -23.63% |
| Change in period | -30.04% |
| Release date | May 07, 2026 |
| Price on release | $24.03 |
| EPS estimate | $0.700 |
| EPS actual | $0.420 |
| EPS surprise | -40.00% |
| Date | Price |
|---|---|
| May 01, 2026 | $21.88 |
| May 04, 2026 | $22.74 |
| May 05, 2026 | $23.39 |
| May 06, 2026 | $23.90 |
| May 07, 2026 | $24.03 |
| May 08, 2026 | $19.00 |
| May 11, 2026 | $18.45 |
| May 12, 2026 | $17.50 |
| May 13, 2026 | $18.32 |
| 4 days before | 9.83% |
| 4 days after | -23.76% |
| On release day | -20.93% |
| Change in period | -16.27% |
Amphastar Pharmaceuticals Earnings Call Transcript Summary of Q1 2026
Amphastar reported Q1 2026 net revenues of $171.2M, a slight increase year-over-year driven by recent product launches and strength in several key brands. BAQSIMI revenue fell ~15% to $32.4M due to lower average selling prices driven by higher rebates/340B discounts (units +8%), and management is taking steps (engaging an outside firm and a 3% list price increase effective May 1) to address duplicate 340B discounts and rebate pressure. Primatene MIST continued to grow (~$29.8M, store sales +6.5% YoY). The recent FDA approval and April launch of ipratropium bromide inhalation (AMP-007) provides a near-term growth driver and currently faces no generic competition. Other product launches (e.g., teriparatide, albuterol, iron sucrose) boosted ‘other finished pharmaceuticals’ revenue. Gross margins were pressured (cost of revenues increased and mix shifts reduced margins); R&D rose 33% to $26.7M as Amphastar invests in biosimilars and proprietary programs. Insulin aspart biosimilar and GLP-1 ANDA remain on track for planned commercial launches in 2027. Cash flow from operations was ~$47.8M and management repurchased $29.5M of stock (~3% of shares). Despite BAQSIMI headwinds, Amphastar is maintaining corporate unit growth guidance of mid-single-digit to high-single-digit for 2026 and emphasizes disciplined investment in branded, biosimilar and proprietary pipelines to drive long-term growth.
